Involvement of the κ-opioid receptor in the anxiogenic-like effect of CP 55,940 in male rats

Pharmacology Biochemistry and Behavior

Volumn 74, Issue 3, 2003, Pages 649-656

  Marin S ^a   Marco, E ^a   Biscaia, M ^a   Fernandez B ^a   Rubio, M ^a   Guaza, C ^b   Schmidhammer, H ^c   Viveros, M P ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b INSTITUTO CAJAL   (Spain)

^c UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Adrenocortical activity; Adult male rat; Anxiety; CP 55,940; Selective , and opioid antagonists

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; CYPRODIME; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR ANTAGONIST; NALTRINDOLE; NORBINALTORPHIMINE; OPIATE ANTAGONIST;

ADRENAL CORTEX; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY; ARTICLE; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DRUG ANTAGONISM; MALE; MAZE TEST; MOTOR ACTIVITY; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT;

ANIMALS; ANXIETY; CANNABINOIDS; CORTICOSTERONE; CYCLOHEXANOLS; MALE; MAZE LEARNING; MOTOR ACTIVITY; NARCOTIC ANTAGONISTS; RATS; RATS, WISTAR; RECEPTORS, OPIOID, KAPPA;

EID: 0037307141     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(02)01041-9     Document Type: Article

References (40)

1. Anseloni V.C.Z., Coimbra N.C., Morato S., Brandão M.L. A comparative study of the effect of morphine in the dorsal periaqueductal gray and nucleus accumbens of rats submitted to the elevated plus-maze test. Exp. Brain Res. 129:1999;260-268.
2. Arévalo C., De Miguel R., Hernández-Tristán R. Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters. Pharmacol. Biochem. Behav. 70:2001;123-131.
3. Arnold J.C., Topple A.N., Hunt G.E., McGregor I.S. Effects of pre-exposure and co-administration of the cannabinoid receptor agonist CP 55,940 on behavioral sensitization to cocaine. Eur. J. Pharmacol. 354:1998;9-16.
4. Arnold J.C., Topple A.N., Mallet P.E., Hunt G.E., McGregor I.S. The distribution of cannabinoid-induced Fos expression in rat brain: differences between the Lewis and Wistar strain. Brain Res. 2001;240-255.
5. Bailey C.C., Kitchen I. Developmental responses to opioids reveals a lack of effect on stress-induced corticosterone levels in neonatal rats. Br. J. Pharmacol. 91:1987;119-125.
6. Berrendero F., Maldonado R. Involvement of the opioid system in the anxiolytic-like effects induced by Delta (9)-tetrahydrocannabinol. Psychopharmacology. 163:2002;111-117.
7. Chaperon F., Thiébot M.-H. Behavioral effects of cannabinoid agents in animals. Crit. Rev. Neurobiol. 13:1999;243-281.
8. Cover P.O., Buckingham J.C. Effects of selective opioid-receptor blockade on the hypothalamus-pituitary-adrenocortical responses to surgical trauma in the rat. J. Endocrinol. 121:1989;213-220.
9. De Rosset S.E., Holtzman S.G. Effects of opiate antagonists and putative kappa agonists on unpunished and punished operant behavior in the rat. Psychopharmacology. 86:1985;386-391.
10. Eisenberg R.M. Effects of naltrexone on plasma corticosterone in opiate-naive rats: a central action. Life Sci. 34:1984;1185-1191.
11. Endoh T., Matsuura H., Tanaka C., Nagase H. Nor-binaltorphimine: a potent and selective kappa-opioid receptor antagonist with long-lasting activity in vivo. Arch. Int. Pharmacodyn. Ther. 316:1992;30-42.
12. Fernández B., Romero E.M., Kitchen I., Viveros M.P. Postnatal naltrindole treatments induce behavioural modifications in preweanling rats. Neurosci. Lett. 283:2000;73-76.
13. File S.E. Behavioral detection of anxiolytic action. Elliot J.M., Heal D.J., Marsden C.A. Experimental approaches to anxiety and depression. 1992;25-44 Wiley, New York.
14. Filliol D., Ghozland S., Chluba J., Martin M., Matthes H.W.D., Simonin F.et al. Mice deficient for δ- and μ-opioid receptors exhibit opposing alterations of emotional responses. Nat. Genet. 25:2000;195-200.
15. Ghozland S., Matthes H.W.D., Simonin F., Filliol D., Kieffer B.L., Maldonado R. Motivational effects of cannabinoids are mediated by μ-opioid and κ-opioid receptors. J. Neurosci. 22:2002;1146-1154.
16. Giuliani D., Ferrari F., Ottani A. The cannabinoid agonist HU 210 modifies rat behavioural responses to novelty and stress. Pharmacol. Res. 41:2000;47-53.
17. Hollister L.E. Health aspects of cannabis. Pharmacol. Rev. 38:1986;1-20.
18. 9 THC and anandamide. Brain Res. 857:2000;337-342.
19. Kelley A.E., Bless E.P., Swanson C.J. Investigation of the effects of opiate antagonists infused into the nucleus accumbens on feeding and sucrose drinking in rats. J. Pharmacol. Exp. Ther. 278:1996;1499-1507.
20. Leventhal L., Cole J.L., Bodnar R.J. Reductions in locomotor activity following central opioid receptor subtype antagonists in rats. Physiol. Behav. 60:1996;833-836.
21. 9-tetrahydrocannabinol in rats. Brain Res. 839:1999;173-179.
22. Manzanares J., Corchero J., Romero J., Fernández-Ruiz J.J., Ramos J.A., Fuentes J.A. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol. Sci. 20:1999;287-294.
23. 8-tetrahydrocannabinol-dimethylheptyl (HU-210), a potent synthetic cannabinoid in rats. Eur. J. Pharmacol. 344:1998;77-86.
24. McGregor I.S., Issakidis C.N., Prior G. Aversive effects of the synthetic cannabinoid CP 55,940 in rats. Pharmacol. Biochem. Behav. 53:1996;657-664.
25. Nobre M.J., Ribeiro dos Santos N., Aguiar M.S., Brandao M.L. Blockade of μ- and activation of κ-opioid receptors in the dorsal periaqueductal gray matter produce defensive behavior in rats tested in the elevated plus-maze. Eur. J. Pharmacol. 404:2000;145-151.
26. Onaivi E.S., Green M.R., Martin B.R. Pharmacological characterization of cannabinoids in the elevated plus maze. J. Pharmacol. Exp. Ther. 253:1990;1002-1009.
27. Pellow S., Chopin P., File S.E., Briley M. Validation of open:closed arms entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods. 14:1985;149-167.
28. Pfeiffer A., Herz A. Endocrine actions of opioids. Horm. Metab. Res. 16:1984;386-397.
29. Pugh G. Jr., Mason D.J. Jr., Combs V., Welch S.P. Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP 55,940 in the spinal cord. J. Pharmacol. Exp. Ther. 281:1997;730-737.
30. 37] CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats. J. Pharmacol. Exp. Ther. 276:1996;56-64.
31. Romero E.M., Fernández B., Sagredo O., Gomez N., Urigüen L., Guaza C.et al. Antinociceptive, behavioural and neuroendocrine effects of CP 55,940 in young rats. Dev. Brain Res. 136:2002;85-92.
32. Sante A.B., Nobre M.J., Brandao M.L. Place aversion induced by blockade of mu or activation of kappa opioid receptors in the dorsal periaqueductal gray matter. Behav. Pharmacol. 11:2000;583-589.
33. Schmidhammer H. Opioid receptor antagonists. Ellis G.P., Luscombe D.K., Oxford A.W. Progress in medicinal chemistry. vol. 35:1998;83-132 Elsevier, Oxford.
34. Skoubis P.D., Matthes H.W., Walwyn W.M., Kieffer B.L., Maidment N.T. Naloxone fails to produce conditioned place aversion in μ-opioid receptor knock-out mice. Neuroscience. 106:2001;757-763.
35. Sofuoglu M., Portoghese P.S., Takemori A.E. Differential antagonism of delta opioid agonists by naltrindole and its benzofuran analog (NTB) in mice: evidence for delta opioid receptor subtypes. J. Pharmacol. Exp. Ther. 257:1991;676-680.
36. Valverde O., Ledent C., Beslot F., Parmentier M., Roques B.P. Reduction of stress-induced analgesia but not of exogenous opioid effects in mice lacking CB1 receptors. Eur. J. Neurosci. 12:2000;533-539.
37. 9-Tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect. Eur. J. Neurosci. 13:2001;1816-1824.
38. Welch S.P., Eads M. Synergistic interactions of endogenous opioids and cannabinoid systems. Brain Res. 848:1999;183-190.
39. Wenger T., Jamali K.A., Juaneda C., Leonardelli J., Tramu G. Arachidonyl ethanolamide (anandamide) activates the parvocellular part of hypothalamic paraventricular nucleus. Biochem. Biophys. Res. Commun. 237:1997;724-728.
40. Zimmer A., Valjent E., König M., Zimmer A.M., Robledo P., Hahn H.et al. Absence of Δ-9-tetrahydrocannabinol dysphoric effects in dynorphin-deficient mice. J. Neurosci. 21:2001;9499-9505.